Theravance Biopharma Inc. (TBPH)
Summary
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Theravance Stock Declines Around 17% in Three Months: Here's Why
TBPH shares sink in three months after its lead drug fails a late-stage study, forcing a pipeline overhaul and raising uncertainty over its future direction.
Theravance Biopharma Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 136 | $1,329.33 | $2,305.2 | $975.87 | 73.41% |
| BG Bart Gancher Intech Investment Management LLC | 13,666 | $123,628.1 | $231,502.04 | $107,873.94 | 87.26% |
 Madison Avenue Partners LP Madison Avenue Partners LP | 9.51M | $80.28M | $161.12M | $80.84M | 100.7% |
 Joseph Castro Nuveen LLC | 127,678 | $1.42M | $2.17M | $742,817.41 | 52.22% |
 Jennifer Grunberg Allspring Global Investments Holdings LLC | 10,783 | $175,008.09 | $182,671.57 | $7,663.48 | 4.38% |
Theravance Biopharma Inc. (TBPH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Theravance Biopharma Inc. ever had a stock split?
Theravance Biopharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Rick E. Winningham CEO | NASDAQ (NMS) Exchange | G8807B106 CUSIP |
| US Country | 90 Employees | - Last Dividend | - Last Split | 16 May 2014 IPO Date |
Overview
Theravance Biopharma, Inc. stands out as a pioneering biopharmaceutical company committed to the discovery, development, and commercialization of groundbreaking respiratory medicines catering to the United States and Europe markets. Established in 2013, the company is anchored in South San Francisco, California, representing an innovative force in the treatment of chronic respiratory conditions. Through its strategic licensing and collaboration agreements with notable industry players such as Pfizer Inc. and Viatris Inc., Theravance Biopharma, Inc. extends its research and development horizons, focusing on delivering therapies that address significant unmet medical needs.
Products and Services
- YUPELRI
A testament to Theravance Biopharma's commitment to respiratory health, YUPELRI emerges as a hallmark treatment for chronic obstructive pulmonary disease (COPD). This once-daily, nebulized long-acting muscarinic antagonist (LAMA) is uniquely designed for the management of COPD, providing patients with a novel approach to controlling their condition.
- Ampreloxetine
As an investigational norepinephrine reuptake inhibitor, Ampreloxetine represents the forefront of Theravance Biopharma's innovative pipeline. Having completed a Phase III study, this potential treatment is specifically targeted at neurogenic orthostatic hypotension (nOH), a condition known for causing a significant drop in blood pressure upon standing. This development underscores the company's dedication to addressing complex neurological conditions through groundbreaking pharmacological approaches.
- TRELEGY
In the realm of combined respiratory therapy, TRELEGY stands as a significant contribution from Theravance Biopharma for the treatment of both COPD and asthma. This product exemplifies the company's broader strategy to enhance the quality of life for patients suffering from chronic respiratory diseases by offering more efficient and convenient treatment options.
